More importantly, our study confirms
that there is an interaction between two genotypes of CYP1A1 polymorphism Akt inhibitor and smoking. For future studies, strict selection of patients, well-matched controls and larger sample size will be required. Moreover, gene-gene and gene-environment interactions MS-275 solubility dmso should also be considered. Acknowledgements This work was supported in part by a grant from the Major Program of Nanjing Medical Science and Technique Development Foundation (Molecular Predictor of Personalized Therapy for Chinese Patients with Non-small Cell Lung Cancer) (Lk-Yu). References 1. Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest 2003, 123:21–49.CrossRef 2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584–594.PubMedCrossRef 3. Alberg AJ, Brock MV, Samet JM: Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005, 23:3175–85.PubMedCrossRef 4. Rodriguez V, Tardon A, Kogevinas M, Prieto CS, Cueto A, Garcia M, Menendez IA, Zaplana J: Lung
cancer risk in iron and steel foundry workers: a nested case control study in Asturias, Spain. Am J Ind Med 2000, 38:644–50.PubMedCrossRef 5. Tardon A, Lee WJ, Delgado-Rodriguez M, Dosemeci check details M, Albanes D, Hoover R, Blair A: Leisure-time physical activity and lung cancer: a meta-analysis. Cancer Causes Control 2005, 16:389–97.PubMedCrossRef 6. Guengerich FP, Shimada T: Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res 1998, 400:201–213.PubMedCrossRef 7. Butler JP, Post
GB, Lioy PJ, Waldman JM, Greenberg A: Assessment of carcinogenic risk from personal exposure to benzo[a]pyrene in the total human environmental exposure study(THEES). J Air Waste Manag Assoc 1993, 43:970–977. 8. Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M: Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996, 56:72–76.PubMed 9. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J: Identification of genetically high risk individuals GNAT2 to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS 1990, 1:131–133.CrossRef 10. Houlston RS: CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics 2000,10(2):105–14.PubMedCrossRef 11. Le Marchand L, Guo C, Benhamou S, Bouchardy C, Cascorbi I, Clapper ML, Garte S, Haugen A, Ingelman-Sundberg M, Kihara M, Rannug A, Ryberg D, Stücker I: Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control 2003,14(4):339–46.PubMedCrossRef 12. Shi X, Zhou S, Wang Z, Zhou Z, Wang Z: CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer 2008,59(2):155–63.PubMedCrossRef 13. Cochran WG: The combination of estimates from different experiments. Biometrics 1954, 10:101–29.